South Korea · Delayed Price · Currency is KRW DuChemBIO Statistics
Total Valuation
DuChemBIO has a market cap or net worth of KRW 255.10 billion. The enterprise value is 264.11 billion.
| Market Cap | 255.10B |
| Enterprise Value | 264.11B |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DuChemBIO has 28.34 million shares outstanding. The number of shares has increased by 5.76% in one year.
| Current Share Class | 28.34M |
| Shares Outstanding | 28.34M |
| Shares Change (YoY) | +5.76% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 9.36% |
| Owned by Institutions (%) | 0.12% |
| Float | 11.01M |
Valuation Ratios
The trailing PE ratio is 39.47.
| PE Ratio | 39.47 |
| Forward PE | n/a |
| PS Ratio | 6.61 |
| PB Ratio | 5.18 |
| P/TBV Ratio | 8.13 |
| P/FCF Ratio | 28.11 |
| P/OCF Ratio | 25.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.48, with an EV/FCF ratio of 29.11.
| EV / Earnings | 40.76 |
| EV / Sales | 6.85 |
| EV / EBITDA | 18.48 |
| EV / EBIT | 35.60 |
| EV / FCF | 29.11 |
Financial Position
The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.50.
| Current Ratio | 1.58 |
| Quick Ratio | 1.50 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 1.71 |
| Debt / FCF | 2.70 |
| Interest Coverage | 7.01 |
Financial Efficiency
Return on equity (ROE) is 14.05% and return on invested capital (ROIC) is 13.69%.
| Return on Equity (ROE) | 14.05% |
| Return on Assets (ROA) | 6.51% |
| Return on Invested Capital (ROIC) | 13.69% |
| Return on Capital Employed (ROCE) | 12.55% |
| Weighted Average Cost of Capital (WACC) | 5.16% |
| Revenue Per Employee | 306.13M |
| Profits Per Employee | 51.43M |
| Employee Count | 126 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 20.79 |
Taxes
In the past 12 months, DuChemBIO has paid 176.72 million in taxes.
| Income Tax | 176.72M |
| Effective Tax Rate | 2.65% |
Stock Price Statistics
The stock price has decreased by -20.35% in the last 52 weeks. The beta is 0.18, so DuChemBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -20.35% |
| 50-Day Moving Average | 9,714.00 |
| 200-Day Moving Average | 9,777.25 |
| Relative Strength Index (RSI) | 43.30 |
| Average Volume (20 Days) | 22,852 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DuChemBIO had revenue of KRW 38.57 billion and earned 6.48 billion in profits. Earnings per share was 228.00.
| Revenue | 38.57B |
| Gross Profit | 14.23B |
| Operating Income | 7.44B |
| Pretax Income | 6.66B |
| Net Income | 6.48B |
| EBITDA | 14.31B |
| EBIT | 7.44B |
| Earnings Per Share (EPS) | 228.00 |
Balance Sheet
The company has 15.45 billion in cash and 24.46 billion in debt, with a net cash position of -9.01 billion or -317.85 per share.
| Cash & Cash Equivalents | 15.45B |
| Total Debt | 24.46B |
| Net Cash | -9.01B |
| Net Cash Per Share | -317.85 |
| Equity (Book Value) | 49.24B |
| Book Value Per Share | 1,737.18 |
| Working Capital | 10.58B |
Cash Flow
In the last 12 months, operating cash flow was 9.94 billion and capital expenditures -865.67 million, giving a free cash flow of 9.07 billion.
| Operating Cash Flow | 9.94B |
| Capital Expenditures | -865.67M |
| Depreciation & Amortization | 6.87B |
| Net Borrowing | -4.42B |
| Free Cash Flow | 9.07B |
| FCF Per Share | 320.12 |
Margins
Gross margin is 36.89%, with operating and profit margins of 19.30% and 16.80%.
| Gross Margin | 36.89% |
| Operating Margin | 19.30% |
| Pretax Margin | 17.26% |
| Profit Margin | 16.80% |
| EBITDA Margin | 37.11% |
| EBIT Margin | 19.30% |
| FCF Margin | 23.52% |
Dividends & Yields
DuChemBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.76% |
| Shareholder Yield | -5.76% |
| Earnings Yield | 2.54% |
| FCF Yield | 3.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DuChemBIO has an Altman Z-Score of 7.47 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.47 |
| Piotroski F-Score | 6 |